Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.

Marwan G FakihHuakang TuHil HsuShivani AggarwalEmily ChanMarko RehnVictoria ChiaEdmund S Kopetz

Published in: The oncologist (2022)

Patients with KRAS p.G12C-mutant mCRC have poor treatment outcomes, and outcomes appear numerically worse than for those without this mutation, indicating potential prognostic implications for KRAS p.G12C mutations and an unmet medical need in this population.

Keyphrases

wild type
metastatic colorectal cancer
healthcare
metabolic syndrome
adipose tissue
skeletal muscle
risk assessment
climate change
weight loss